The EIF4EBP1 Knockout CAL-27 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population of CAL-27 cells with disruption of the EIF4EBP1 gene. This polyclonal knockout model enables loss-of-function studies of the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) in a human oral squamous cell carcinoma background. The polyclonal nature of the edited cell pool reflects a heterogeneous mixture of gene-disrupted alleles, facilitating pooled phenotypic analyses without single-cell cloning. This cell product serves as a versatile tool for investigating mTOR-dependent translational control in cancer research.
CAL-27 cells are an adherent epithelial cell line derived from a human tongue squamous cell carcinoma. As a model of oral cavity malignancy, CAL-27 cells retain key characteristics of head and neck squamous cell carcinoma, including aberrant growth signaling and invasive potential. This host cell line is widely employed to study molecular mechanisms driving oral cancer progression, metastasis, and therapeutic resistance, making it a relevant platform for interrogating EIF4EBP1 function in a disease-relevant context.
EIF4EBP1 functions as a critical translational repressor by binding to the cap-binding protein eIF4E, thereby inhibiting cap-dependent translation initiation. Under growth-promoting conditions, the mTORC1 kinase complex, which includes Raptor and integrates signals from PI3K/AKT, insulin/IGF-1, nutrients, and growth factors, phosphorylates EIF4EBP1. This phosphorylation induces dissociation of EIF4EBP1 from eIF4E, releasing eIF4E to assemble the translation initiation complex and drive synthesis of growth-related proteins such as cyclin D1, c-Myc, and VEGF. The mTORC1-EIF4EBP1-eIF4E axis is a central hub in the PI3K/AKT/mTOR pathway, with S6K1 acting downstream in parallel.
In CAL-27 oral squamous cell carcinoma cells, the PI3K/AKT/mTOR pathway is frequently hyperactivated, contributing to uncontrolled proliferation and survival. Disruption of EIF4EBP1 in this genetic background can unmask or modulate the translational output of oncogenic mRNAs and may alter sensitivity to mTOR inhibitors. This knockout model enables dissection of EIF4EBP1-dependent and -independent functions of mTORC1 signaling in a malignant epithelial context, offering insights into translation control mechanisms underlying head and neck cancer pathogenesis.
Researchers can apply this polyclonal knockout cell population to study mTOR signaling kinetics, cap-dependent translation regulation, and drug resistance mechanisms. Representative experimental approaches include western blotting for phospho-4E-BP1 to assess mTORC1 activity, cap-binding assays, polysome profiling, RT-qPCR for target mRNAs (e.g., cyclin D1, c-Myc), immunofluorescence, and flow cytometry for cell cycle analysis. The cells are also suitable for evaluating mTOR inhibitor responses in functional viability or apoptosis assays. For additional product information and technical support, please contact Ascent Research.
